XOMA Royalty (XOMA) Net Income towards Common Stockholders Growth (5y) (2016 - 2026)
XOMA Royalty (XOMA) Net Income towards Common Stockholders Growth (5y) (2016 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
| 10 |
XOMA Royalty |
5.48 Mn |
-60.60 Mn |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
21.11% |
| Dec 31, 2025 |
-25.75% |
| Sep 30, 2025 |
72.72% |
| Jun 30, 2025 |
18.98% |
| Mar 31, 2025 |
20.09% |
| Dec 31, 2024 |
33.65% |
| Sep 30, 2024 |
-49.33% |
| Jun 30, 2024 |
-27.05% |
| Mar 31, 2024 |
-39.40% |
| Dec 31, 2023 |
-45.93% |
| Sep 30, 2023 |
-4.80% |
| Jun 30, 2023 |
-25.06% |
| Mar 31, 2023 |
-21.72% |
| Dec 31, 2022 |
-36.34% |
| Sep 30, 2022 |
-16.72% |
| Jun 30, 2022 |
-79.68% |
| Mar 31, 2022 |
33.86% |
| Dec 31, 2021 |
29.97% |
| Sep 30, 2021 |
18.75% |
| Jun 30, 2021 |
34.83% |
